Clinical Trials Logo

Recombinant Zoster Vaccine clinical trials

View clinical trials related to Recombinant Zoster Vaccine.

Filter by:
  • None
  • Page 1

NCT ID: NCT04516408 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Recombinant Zoster Vaccine in Stable SLE Patients

Start date: April 20, 2021
Phase: N/A
Study type: Interventional

The risk of herpers zoster reactivation is higher in SLE patients than general population. It has shown that mild or even inactive patients could also have varicella zoster virus (VZV) infections, and they account for about two-thirds of the events. And our previous study indicated that recent various VZV infection was associated with increased risk of disease flares. The risk of virus reactivation limited the use of live-attenuated shingles vaccine in SLE patients, especially in whom with high dose of prednisone or immunosuppressants. Whether the introduction of recombinant zoster vaccine could reduce the risk of zoster reactivation in lupus patients is to be explored in this study.